Abstract 4785
Background
Thymoma and thymic carcinoma (TC) are rare diseases of thymus with relatively good prognosis. Different pathological sub-types of thymoma and TC show clear differences on clinical characteristics, morphology, molecular markers, and prognosis.
Methods
In this study, 26 thymoma and thymic carcinoma patients with most common thymic epithelial tumor subtypes were enrolled, including 2 type A, 6 type AB, 3 type B1, 1 type B1/B2, 5 type B2, 2 type B2/B3, 4 type B3, and 3 type TC patients in total. The frozen tissues of all patients were processed for RNA-seq sequencing.
Results
We used unsupervised clustering to divide all samples into 5 clusters. Four clusters showed clear concordance with pathological subtypes, i.e. cluster AB (5 AB, 1 B1, and 2 B2), cluster B1/B2 (2 B1, 1 B1/B2, and 2B2), cluster B2/B3 (1 B2, 1 B2/B3, and 2B3), and cluster TC (3 TC and 1 A). Only one cluster (1 A, 1 AB, and 2 B3) was labeled as cluster A/AB according to the result of joint clustering analysis with TCGA THYM RNA-seq data. We performed gene function enrichment analysis on highly expressed genes in each cluster. Cluster A showed gene function enrichment on two development related pathways (nervous system development and epithelium development) and cell differentiation. Cluster AB had enriched function of cell proliferation and regulation of cell development. Cluster B1/B2 did not show any enriched functions. Cluster B2/B3 showed gene function enrichment of cell adhesion and regulation of developmental process. CD274 (PD-L1) was also highly expressed in this cluster. Cluster TC had enriched function of several pathways, including cell adhesion, cell migration, cell differentiation, immune system process, immune response, and nervous system development. Moreover, PI3K-Akt signaling pathway, pathway in cancer, and transcriptional misregulation in cancer were also enriched in cluster TC’s highly expressed genes.
Conclusions
Thymic epithelial tumor subtypes show clearly different expression profiles. The highly expressed genes of each subtype relate to development, immune, and cancer related functions. PD-L1 is highly expressed in B2/B3 samples which suggests potential immunotherapy for the subtypes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peking Union Medical College Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2831 - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia
Presenter: Salah Khallaf
Session: Poster Display session 1
Resources:
Abstract
6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)
Presenter: Su-peng Yeh
Session: Poster Display session 1
Resources:
Abstract
2914 - Efficacy endpoints studied in clinical trials for early-onset leukaemia
Presenter: Dylan Said
Session: Poster Display session 1
Resources:
Abstract
4691 - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia
Presenter: Tomohiro Yamakawa
Session: Poster Display session 1
Resources:
Abstract
4395 - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Presenter: Suzanne Trudel
Session: Poster Display session 1
Resources:
Abstract
2808 - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Nathan Fowler
Session: Poster Display session 1
Resources:
Abstract
4403 - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Jonathon Cohen
Session: Poster Display session 1
Resources:
Abstract
3357 - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
2475 - Qualitative study of patients’ experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services
Presenter: Ana Martins
Session: Poster Display session 1
Resources:
Abstract
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract